Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Core Viewpoint - Passage Bio, Inc. is actively engaged in the development of genetic medicines aimed at treating neurodegenerative diseases, with a focus on innovative one-time therapies [3]. Company Overview - Passage Bio is a clinical stage genetic medicines company dedicated to improving the lives of patients suffering from neurodegenerative diseases [3]. - The company's lead product candidate, PBFT02, targets conditions such as frontotemporal dementia by increasing progranulin levels to restore lysosomal function and slow disease progression [3]. Upcoming Events - Will Chou, M.D., the president and CEO of Passage Bio, will participate in a fireside chat at the Guggenheim Securities 2 Annual Healthcare Innovation Conference on November 12, 2025, at 9:30 a.m. ET in Boston, MA [1]. - A live webcast of the event will be accessible on the Investors & News section of Passage Bio's website, with a replay available for 90 days post-event [2].